Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey

ObjectivesThe health-related quality of life (HRQoL) and utilities of patients with chronic hepatitis B (CHB) virus infection, including compensated cirrhosis (CC), decompensated cirrhosis (DC) and different stages of hepatocellular carcinoma (HCC), have not been well described in China. This study aimed to evaluate HRQoL and utilities and provide parameters for the economic evaluation of CHB-related diseases.MethodsWe conducted a multicentre cross-sectional and study to measure the HRQoL of patients with CHB, CC, DC and HCC using the Chinese short form (SF) 36 health survey V.2. The utilities were extracted based on the SF-six dimension scoring model. Multivariable regression analyses identified the effects on HRQoL.ResultsA total of 1071 patients (639 with CHB, 125 with CC, 85 with DC and 222 with HCC) were invited to complete the questionnaire. Physical HRQoL was not impaired in the CHB stage, while mental HRQoL was significantly impaired. Physical composite summary scores have a more significant decrease than mental composite summary scores at the advanced stages (CC, DC and HCC). The utility scores of CHB only, CC, DC and HCC were 0.773, 0.750, 0.683 and 0.640, respectively. The utility scores in the early, middle and terminal stages of HCC were 0.656, 0.635 and 0.615, respectively.ConclusionSlowing the progress of CHB-related diseases and providing psychological support early are the key points to improving the quality of life with the diseases. The utility values estimated in this study can provide a vital instrument for cost-effectiveness studies on CHB-related diseases.

Download Full-text

Socioeconomic Vulnerability to Depressive Symptoms in Patients with Chronic Hepatitis B

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph16020255 ◽

2019 ◽

Vol 16 (2) ◽

pp. 255 ◽

Cited By ~ 6

Author(s):

Thuc Vu ◽

Thieu Le ◽

Anh Dang ◽

Long Nguyen ◽

Binh Nguyen ◽

...

Keyword(s):

Quality Of Life ◽

Chronic Hepatitis ◽

Depressive Symptoms ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Multivariate Logistic Regression Model ◽

Health Related Quality ◽

Related Quality ◽

Health Related

Depression is considered one of the most prevalent psychiatric disorders among patients with hepatitis B virus (HBV)-related liver disease and has adverse effects on the disease progression. However, there is a scarcity of studies contributing to the assessement of depression in hepatitis B patients. There is also little research into risk factors, particularly underlying socio-economic factors in Vietnam where the prevalence of hepatitis B is high. This study aimed to examine depression and identify whether differences in socio-economic status is related to the level of depression amongst chronic hepatitis B patients. A cross-sectional study was conducted on 298 patients with chronic hepatitis B at The Chronic Hepatitis Clinic in the Viet-Tiep Hospital, Hai Phong, Vietnam. The Patient Health Questionnaire-9 (PHQ-9) and EuroQol-5 dimensions-5 levels (EQ-5D-5L) were used to assess the severity of depression and health-related quality of life (HRQOL). Of chronic hepatitis B patients, 37.5% experienced depressive symptoms and most of them suffered minimal depressive symptoms (31.4%). According to the result of the multivariate logistic regression model, we found that higher age, lower income level, unemployement, living with spouse/partners were positively associated with having depression. Furthermore, having physical health problems and lower health-related quality of life were also related to a higher risk of depression. We recommend family support, financial support and active participation in consultation should be conducted during treatment to improve the quality of life and the emotional state of HBV patients.

Download Full-text

P1-053: Assessment of health-related quality of life in patients with chronic hepatitis B

Journal of Viral Hepatitis ◽

10.1111/jvh.31_12923 ◽

2018 ◽

Vol 25 ◽

pp. 50-51

Keyword(s):

Quality Of Life ◽

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Health Related Quality ◽

Related Quality ◽

Health Related

Download Full-text

Impairment of health-related quality of life in patients with asymptomatic chronic hepatitis B or C in the United Kingdom

Journal of Hepatology ◽

10.1016/s0168-8278(00)80763-1 ◽

2000 ◽

Vol 32 ◽

pp. 112 ◽

Cited By ~ 3

Author(s):

M. Thursz ◽

R. Rahman ◽

C. Murphy ◽

J. Robinson ◽

D. Rosenberg ◽

...

Keyword(s):

Quality Of Life ◽

Chronic Hepatitis ◽

United Kingdom ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Health Related Quality ◽

The United Kingdom ◽

Related Quality ◽

Health Related

Download Full-text

Evaluation on quality of life and analysis on its correlation with TCM syndromes in patients of chronic hepatitis B

Chinese Journal of Integrative Medicine ◽

10.1007/s11655-009-0030-z ◽

2009 ◽

Vol 15 (1) ◽

pp. 30-33 ◽

Cited By ~ 1

Author(s):

Wei Zhang ◽

Li-qiong Wang ◽

Yi-bo Liu

Keyword(s):

Quality Of Life ◽

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B

Download Full-text

SHOULD CHRONIC HEPATITIS B BE TREATED AS EARLY AS POSSIBLE?

International Journal of Technology Assessment in Health Care ◽

10.1017/s0266462312000736 ◽

2013 ◽

Vol 29 (1) ◽

pp. 35-41 ◽

Cited By ~ 5

Author(s):

Frank Hulstaert ◽

Christoph Schwierz ◽

Frederik Nevens ◽

Nancy Thiry ◽

Mohamed Gamil ◽

...

Keyword(s):

Quality Of Life ◽

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Disease Stage ◽

Multicenter Survey ◽

Cirrhotic Patients

Objectives: We studied the cost-effectiveness of tenofovir and entecavir in e antigen positive (CHBe+) and negative (CHBe-) chronic hepatitis B.Methods: Using a multicenter survey including 544 patients we measured patient quality of life and attributable costs by clinical disease stage. Natural disease progression was studied in 278 patients in a single center. A Markov model was constructed to follow hypothetical cohorts of treated and untreated 40-year-old CHBe+ and CHBe- patients and 50-year-old patients with compensated cirrhosis.Results: We did not find an improvement in quality of life when viral load was reduced under treatment. Transition rates to liver cirrhosis were found to be age-dependent. Assuming equal effectiveness, tenofovir dominates the entecavir strategy because of its lower price in Belgium. The incremental cost-effectiveness ratio (ICER) of tenofovir after 20 years is more favorable for treating Caucasian cirrhotic patients (mean ICER €29,000/quality-adjusted life-year [QALY]) compared with treating non-cirrhotic patients (mean ICER €110,000 and 131,000/QALY for CHB e+ and e-, respectively). Within the non-cirrhotic patients the ICER decreases with increasing cohort starting age from 30 to 50 years.Conclusions: Results of long-term models for tenofovir or entecavir treatment of CHB need to be interpreted with caution as long-term trials with hard end points are lacking. Especially the effect on HCC remains highly uncertain. Based on cost-effectiveness considerations such antiviral treatment should be targeted at patients with cirrhosis or at risk of rapid progression to this disease stage.

Download Full-text